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acidic culture conditions, an in vitro cancer model/microenvironment that is more physiologically relevant
may be engineered to produce results more readily applicable to the clinic.
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Despite improvements in our understanding of the mechanisms of
cancer pathogenesis and the continuous development of novel
therapeutics, advanced cancers are in general still not curable. There is
therefore a critical need for more effective treatments to improve dis-
ease management and patient survival. Use of in vitro cancer models
has provided valuable information onthe understanding of cancer de-
velopment andmechanisms of therapeutic action as they allow detailed
analysis of these subjects under controlled conditions. As well, cancer
cells grown in suspension culture, or as monolayers on plastic surfaces,
are commonly used as cancermodels in preclinical drug efﬁcacy screen-
ings. Major deﬁciencies of such models, however, include the lack of
heterogeneity reﬂective of the original malignancy as well as an im-
proper microenvironment, both of which are identiﬁed asmajor factors
inﬂuencing cancer development and treatment resistance [1–3]. The
poor resemblance of these in vitro models to human cancers and their
microenvironments is considered a major reason why many preclinical
ﬁndings fail to translate directly into clinical applications and the basis
of the lack of predictive power of cultured cell-based models for drug
efﬁcacy and toxicity in humans [4]. As such, clinical tumor physiology,
in addition to molecular and cellular biology, should be considered in
the development of improved experimental cancer models.
To improve the clinical relevance of in vitro cancer models, it
appears imperative to (i) use clinically relevant cancer tissue/cells
that better represent the heterogeneity and complexity of cancers and
(ii) mimic the tumor microenvironment more accurately. AlthoughFig. 1.Heterogeneity of a patient's tumor compared to homogeneity of cell linemodels. A sectio
highly heterogeneousmorphology. A–C: pattern of highGleason grade (Grade 4); D–F: pattern o
patient-dervied xenograftmodels (panel 2), it is lostwhen using a cell linemodel in vivo (panel
PC3 prostate cancer cell culture).signiﬁcant progress has been made over the past decade in the design
of such models, current approaches still need further reﬁnements that
will allow reliable high-throughput analyses. In this review, we will
discuss considerations regarding the use of in vitro systems of cancer
cells/tissue, and then focus on critical microenvironmental factors ob-
served in patient-derived xenografts and in the clinic that are worth
contemplating. While it is expected that it will not be feasible to design
in vitro systems that perfectly mimic themalignancy and its microenvi-
ronment, since that would likely lead to their loss of simplicity and ease
of use, improvements in certain crucial aspects of cancer biologymay be
considered for the construction of clinically more relevant in vitro
cancer models.
2. Tumor heterogeneity and model ﬁdelity
The cellular and molecular heterogeneity of human cancers is well
accepted. Tumor heterogeneity presents one of the greatest obstacles
in model-based development of cancer therapeutics. Established
human cancer cell lines can provide simpliﬁed cancer models and are
commonly used in the preclinical studies of the disease. Such cell lines
are valuable for basic studies but, unfortunately, have limited ability
for predicting anti-cancer drug efﬁcacy in the clinic [5]. One reason for
this shortcoming is the relatively high homogeneity of established cell
lines, a consequence of clonal selection during culturing, which is
in contrast with the cellular heterogeneity of the parental tumors
(Fig. 1). Furthermore, in vitro culture conditions can introduce
additional evolutionary pressures such as oxidative stress [6], leadingnedwhole-mount patient's prostate imaged at different cancerous regions (panel 1) show
f lowGleason grade (Grades 2–3).While this heterogeneity can bemostly recapitulated in
3: image of PC3 prostate cancer cell line tumor grown in vivo) or in vitro (panel 4: image of
224 S.Y.C. Choi et al. / Advanced Drug Delivery Reviews 79–80 (2014) 222–237to genetic and phenotypic changes that accumulate with repeated
subculturing [7–10]. The clonal selection and long-term passage of
cells in vitro thus result in homogeneous cancer cell populations
adapted to particular culture conditions that greatly differ from cancer
cell populations present in patients' tumors.
2.1. Patient-derived xenograft (PDX) models
More realistic preclinical cancer models are thought to be provided
by transplantable, patient-derived cancer tissue xenograft (PDX) lines
based on the grafting of fresh cancer tissue specimens subcutaneously,
orthotopically or under the kidney capsules of immunodeﬁcient mice
(e.g., NOD-SCID, NSG mice). At the histopathological level, the PDX
models retain, especially initially, the architecture and stromal compo-
nents of the original tumor and therefore are thought tomore accurate-
ly represent the complex biochemical and physical interactions
between the cancer cells and their microenvironment [11,12]. At the
cellular level, PDX models also preserve the inter-tumoral and intra-
tumoral heterogeneity, aswell as the phenotypic andmolecular charac-
teristics of the original cancer, including chromosomal copy number
variants [13–15], single-nucleotide polymorphisms [16,17], and gene
expression proﬁles [13,17–20]. In view of this, cancer tissues, or cells,
derived from PDXmodels thatmimic the biological andmolecular char-
acteristics of the original cancer with high ﬁdelity could be employed to
provide clinicallymore relevant in vitro cancermodeling systems. More
speciﬁcally, such PDX tissues could be used to represent primary tumor
samples from patients, either through the maintenance of tissue ex-
plants in vitro [21,22] or through establishment of primary cell cultures
[23–25]. In addition to better mimicking the heterogeneity and biologi-
cal characteristics of the original malignancy, use of cancer tissue
xenografts has the advantage that the original tissue can be serially
propagated in vivo. This results in more materials being available for
repeated experimentation and potentially alleviates limitations
pertaining to the inconvenience of patients' samples. Tomore fully rep-
resent the range of biological and molecular characteristics of patients'
tumors, a panel of established xenograft lines covering multiple cancer
tissues of origin and subtypes is required for the selection of the most
appropriate model to address particular experimental problems.
2.2. Humanized in vivo models
In addition to the use of PDXmodels, another strategy used in vivo to
improve the clinical relevance of cancermodels is the use of humanized
chimeric animals. While traditional in vivo studies often make use of
human cancers transplanted into immunocompromised rodents, the in-
compatibilities between tumor and host often result in disruptions of
critical native processes requiring species-speciﬁc interactions [26].
Efforts have therefore been made to incorporate additional human
components into host animals to mitigate these differences and to
better mimic the human disease, either through genetic engineering
approaches to introduce human versions of certain genes [27], the
seeding of human immune cells or stromal components [28,29], or
through implantation of human organoids [30–32]. More importantly,
observations from such studies have demonstrated that tumormicroen-
vironmental factors can greatly impact certain aspects of cancer cell be-
havior. For example, while bone metastasis is a common clinical
presentation of variousmalignancies such as breast and prostate cancer,
the mechanisms involved still remain largely unknown due to the lack
of appropriate in vivo models. However, it has been shown that by
humanizing the primary tumor site [31,33], or by using human or
tissue-engineered bone grafts as target metastatic sites [30,34,35], the
osteotropic phenotype can be recapitulated to study the underlying
factors involved. The application of such in vivo models is not limited
to cancer and has also been used to study various aspects of immunolo-
gy and toxicology [36,37]. Fundamentally, these studies serve to
demonstrate that the microenvironment of the cancer is of criticalimportance and can greatly inﬂuence experimental outcomes, thus
highlighting the need for better mimicking of the tumor microenviron-
ment in order to improve the clinical relevance of in vitro models.
3. Tumor microenvironmental factors
The tumor microenvironment is the cellular andmolecular environ-
ment inwhich the tumor exists. In addition to cancer cells, themicroen-
vironment includes surrounding lymphatic and blood capillaries,
immune cells such as lymphocytes and macrophages, ﬁbroblasts,
other normal cells, the extracellular matrix (ECM), and a variety of
signaling molecules. Alterations to microenvironmental conditions
may promote unrestrained cell proliferation [38], facilitate tumor initia-
tion [39], and direct metastasis [40]. For example, as tumors develop, a
shift in tissue dimensionality can occur through the loss of epithelial
polarity [41] and alignment of ECM ﬁbers [42,43]. The resulting changes
in cell–cell contact can alter paracrine signaling and signiﬁcantly
contribute to disease progression [44]. Furthermore, aberrant tumor
vascular function, including irregular and premature vascular networks,
inadequate microcirculation and high vascular permeability, also
contributes to the development of an adverse pathophysiological cancer
microenvironment [45,46]. It can lead to hypoxia, upregulation of glyco-
lytic capacity and lactate accumulation, extracellular acidosis, nutrient
deprivation and energy depletion, andATP hydrolysis and adenosine ac-
cumulation [47–50]. Hypoxia, in particular, is a commonly witnessed
condition in most tumor masses and often contributes to mutagenesis,
suppression of apoptosis, and epithelial-to-mesenchymal transition,
among other effects on tumor biology [47,48]. Moreover, exosomes pro-
duced by cancer cells have been demonstrated to serve as an active
mechanism of communication between the tumor and its microenvi-
ronment and could play a role in treatment resistance, metastasis and
immune suppression [51,52].
Given the highly complex nature of the tumor microenvironment
and its components, it is likely that many microenvironmental factors
can contribute to cancer growth and progression. Rather than exhaus-
tively deﬁning every possible one, a few crucial but relatively underap-
preciated characteristics of the in vivo tumormicroenvironment, drawn
from our experience with PDX models, are highlighted below for con-
sideration. They include the tumor architecture and its pathophysiolog-
ical features, cell–cell interactions within the tumor, and high acidity of
the tumor microenvironment. While other components of the tumor
microenvironment are also highly relevant, extensively describing
each element and fully acknowledging all contributors to the various
ﬁelds are regretfully beyond the scope of this review. A summary of
the various components as well as sources for additional information
have been listed (Table 1).
3.1. Tumor architecture
One advantage of the PDX models is the retention of the original
tumor architecture. While cancer cell lines are frequently transplanted
into animals as a method of establishing tumors in vivo, the resultant
tumors do not exhibit the distinct histological characteristics observed
in the clinic (Fig. 1). One important consideration in this regard is that
cells within tissues are surrounded by the ECM, a meshwork of proteins
and proteoglycans such as laminin, collagen and ﬁbronectin. It provides
structural support, stability, ﬂexibility and shape for the tissue and also
mediates cell polarity, intracellular signaling and cell migration [53,54].
Inside the cells, ECM-induced signaling pathways are transmitted
mainly through integrin molecules (i.e. heterodimeric transmembrane
receptors that mediate cell adhesion to the ECM) and molecules of the
immunoglobulin superfamily. Integrins act as bridges between the
ECM and the internal cytoskeleton by transducing key intracellular
signals through associating with clusters of kinases and adaptor pro-
teins in focal adhesion complexes [55]. These interactions have been
found to be distinctly mediated by speciﬁc integrin heterodimers
Table 1
Summary of various important components/factors of the tumor microenvironment and additional references for more detailed information.
Relevant factors of the tumor
microenvironment
Summary In vitro mimics References for additional
information
ECM alterations Tumors have increased collagen I deposition. Furthermore, it has been shown
that tumors may have altered expression of collagen-modifying enzymes that
ultimately affect cell invasive and metastatic potentials through increased
matrix stiffness and alignment of ﬁbers at the invasive edge.
Use of different ECM compositions
in 3D cultures
[278]
Immunosuppressive
microenvironment
Localized suppression of the anti-cancer immune response occurs through
various mechanisms, such as expression of immunosuppressive cytokines,
recruitment of regulatory immune cells, or expression of immune inhibitory
signaling molecules.
Co-culture systems with immune
cells
[279–282]
Addition of cytokines to culture
medium
Acidic tumor
microenvironment
Results from altered cancer metabolism and the overproduction of lactic acid.
Alternatively, overexpression of other pH modulatory proteins such as NHEs
and V-ATPases has also been implicated. Promotes various cancer
characteristics such as angiogenesis, tissue invasion, therapy resistance, and
immunosuppression.
Acidic culture conditions [236,267,283,284]
Hypoxia Oxygen tension within the tumor often ﬂuctuates between normoxic and
hypoxic conditions due diffusion limitations and abnormal vasculature. Poor
oxygenation is particularly pertinent to radioresistance. Although expression of
oxygen responsive genes is primarily mediated through HIF-1α, additional
signaling pathways such as mTOR, Myc, and Notch have also been implicated.
Furthermore, low oxygen levels can also alter various tumor stromal
components.
Environmentally controlled
chambers for culturing in hypoxic
conditions
[47,278,285–287]
Chemical inducers of hypoxic
response
Necrosis/necroptosis Cell death characterized by ruptured membranes and spilling of cytoplasmic
content into the extracellular space. Recent studies have shown that necrosis is
a regulated process much like apoptosis (referred to as programmed necrosis, or
necroptosis) involving TNFR, RIPK and calcium signaling. This mode of death in
the tumor, particularly following therapy, results in the release of pro-
inﬂammatory damage-associated molecular patterns into the tumor
microenvironment and may initiate an anti-cancer immune response.
Death receptor ligation with
caspase inhibitors
[288–291]
Apoptosis-deﬁcient cell models
Exosomes Emerging as an important mechanism of cell–cell communication. Cancer-
derived exosomes have been shown to contain a large array of proteins and
RNAs that help survival, drive progression, establish premetastatic niches, and
modulate anti-cancer immunity.
Exosome isolation from culture
supernatant or patient serum
[51,52]
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via the cytoskeleton to the nuclear matrix and affect gene expres-
sion [57]. As such, highly speciﬁc and localized signaling cascades can
be activated by the ECM in association with various available growth
factors through sequences of reactions involving networks of proteases
and sulfatases [58].
The biophysical interplay between the cell and the ECM also
establishes a dynamic mechanical reciprocity as its maintenance and
homeostasis involve a tight balance between the biosynthesis, three-
dimensional (3D) organization, cross-linking, and degradation of ECM
proteins [58–60]. Furthermore, cell behavior within tissues is largely
based on the 3D interactions of cells with the ECM and other cells, and
on the responses to various mechanical stimuli. The correct architec-
ture/structure is therefore another critical factor to consider in addition
to the composition of the ECM. In fact, dimensional changes can inﬂu-
ence tumor growth [61–63], cell migration [64], signaling [65] and
drug response [66] independent of other phenotypic changes. This
may partially explain frequent discrepancies between bench top and
clinical efﬁcacy of new therapies [67].
It has been reported that the architectural, biochemical and physical
properties of cancer ECM are different from normal tissue. For example,
breakdown of the epithelial basal membrane is a histologic hallmark of
malignant tumors, and there is evidence to support that subtle changes
in ECM preceding its complete breakdown can actively contribute to
cancer initiation and progression [68]. Furthermore, tumor stroma is
usually stiffer than normal, which enhances cell growth and survival
and promotes cell migration [69]. There is also an increase in collagen
gene expression and deposition along with an overproduction of hepa-
rin sulfate proteoglycans during tumor formation [70–72]. Additionally,
cancer-associated blood coagulation forms ﬁbrin clots within or adja-
cent to cancer tissues, which are subsequently replaced by collagenous
stroma in a process similar to that in normal wound healing, further
contributing to the abundant tumor stroma in highly invasive tumors
[73,74]. It has also been reported that collagen I in cancer tissue ishighly linearized and oriented adjacent to the epithelium, projecting
perpendicularly into the tissue instead of forming relaxed non-
oriented ﬁbrils [69,75]. Increased expression of many ECM remodeling
enzymes including matrix metalloproteinases (MMPs), urokinase,
heparanases, and cysteine cathepsins is also often observed in a number
of cancers [76,77]. The deregulation and disorganization of the ECM in
cancermay greatly impact various signaling pathways and can promote
malignant transformation, survival, and proliferation of cancer cells [78]
. In view of these ﬁndings, using the correct type and composition of
ECM in vitro to mimic altered tumor matrix could allow for analysis of
cancer cell behavior in a more clinically relevant environment.
3.1.1. ECM components and 3D cultures
Various natural, semisynthetic and synthetic materials have been
used to simulate tumor ECM in cultured cell systems, and important in-
sights into tumorigenesis have been gained from their use. In particular,
Matrigel, a basement membrane matrix preparation derived from
murine sarcoma, and ECM components, derived from animal tissues
such as collagen-I, laminin and ﬁbronectin, are widely accepted in
view of their intrinsic cytocompatibility, allowance for cell adhesion
and ability tomodify gel properties, such as ﬁber structure and porosity,
by altering gelling conditions (e.g., temperature, gel concentration, pH
and media components) [79]. However, the barrier properties of the
natural basementmembrane are dependent on covalent cross-links be-
tween collagen type IV molecules, which are destroyed in the isolation
and solubilization processes of Matrigel [80]. Therefore, mechanistic
studies of epithelial migration through soluble Matrigel may not be
able to fully identify the molecular and cellular components involved
in tumor progression and tissue invasion. For collagen matrices, a criti-
cal determinant of cell migration is the formation of ﬁbers [81], which
differs between pepsin- and acid-solubilized collagen. While acid-
soluble collagen ﬁbers reﬂect the natural structure of collagen in vivo,
it contains telopeptides that may negatively affect biocompatibility
[82]. Studies using collagen matrices should hence be carefully
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into consideration [44]. One possible alternative is the use of
cell-derivedmatrices (CDM), which contain ECM components naturally
produced when certain types of cells (e.g. ﬁbroblasts) are cultured at
high density in vitro. It has been shown that CDM closely mimics the
chemical and physical properties of in vivo matrix in terms of diversity,
spatial heterogeneity, ﬂexibility, and stiffness [83]. Recent studies have
also shown that the CDM produced by cancer-associated ﬁbroblasts re-
capitulated the architecture and content observed in parental tissue
stroma [84,85]. In addition, cancer-associated CDM was sufﬁcient and
necessary to promote desmoplastic differentiation of normal ﬁbroblasts
and trigger tissue invasive behavior of breast cancer cells [85,86]. As
such, CDM can be considered a more complex, physiologically relevant
alternative to puriﬁed protein matrices.
It has been reported, however, that culturing cells on ECM protein-
coated polymer surfaces does not necessarily lead to in vivo-like cell
behavior. It has become apparent that traditional two-dimensional
(2D) culture approaches are inadequate in mimicking the 3D space of
the original cancers. In view of this, 3D cultures are more suitable for
modeling the tumor microenvironment in vitro since they can simulate
the dimensional aspects of tumors in a controlled fashion. Merely
switching culture dimensionality from 2D to 3D radically affects protein
expression [87], cell proliferation [88], differentiation [89], andmetabo-
lism [90]. 3D in vitro models are here only brieﬂy discussed since they
have been thoroughly reviewed elsewhere [91–94] and are not the
main focus of this review.
3D cultures bridge the gap between traditional 2D cultures and
in vivo animal models. In the last decade, increased use of 3D models
that mimic speciﬁc tissues have signiﬁcantly improved the understand-
ing of the mechanisms of tumor development and facilitated the devel-
opment and screening of new therapeutics. 3D models allow rapid
experimentalmanipulations and their format can be tailored to suit par-
ticular scientiﬁc problems and downstream uses. On the other hand, it
should be noted that 3D cultures do not fully reproduce the in vivo
tumor microenvironment, as systemic effects are notably absent. Also,
establishing these models can introduce alternate factors that may
modulate cell behavior, such as cellular conﬁnement affecting cellular
stiffness responses, and steric hindrance altering diffusion of secreted
molecular signals [44,95,96]. Therefore, the results generated in 3D
culture systems must be interpreted cautiously and need to be further
validated in vivo. While the advantages and limitations of various 3D
culture systems have been well reviewed by others [92,97–99], a few
major points are worth noting. Although the concentration of collagen
matrices can be adjusted to mimic the density of a particular tissue
under study, these matrices lack other ECM components and may
have altered covalent crosslinks [92]. Alternatively, Matrigel may
mimic the basement membrane as it contains basement membrane
components, but its presence as a 3D gel is vastly different from the
thin layer found separating and supporting the epithelium [97]. Cell-
derivedmatrices can have lower amounts of collagen and larger internal
spaces [83]. Finally, in addition to considering the properties of the
various available matrix materials and their potential effects on cell be-
havior, it is also important to consider the matrix characteristics of the
speciﬁc tissue of origin. The proper considerations pertaining to partic-
ular cancer types are discussed in greater detail by other reviews in this
issue.
3.2. Cell–cell interactions
Early seminal experiments have demonstrated thatmalignant prop-
erties of cells isolated from cancers can be reversed when they are
placed in themidst of the normal tissue of origin [100]. Such discoveries
bring into question the very nature of cancer cells and the details re-
garding their existence in the ﬁrst place. While contradictory to the
commonly accepted somaticmutationmodel, a proposed tissue organi-
zation ﬁeld theory (TOFT) suggests that cancer is a tissue-based diseasegenerated as naturally proliferating cells are liberated from restraints
imposed by their microenvironment. Environmental factors disrupting
the communication between cells and their extracellular matrix could
be the driving force behind the development of neoplasia [101–103].
Additionally, it is well documented that cell–cell interaction plays an
important role in this process. Many cell types, including ﬁbroblasts,
smooth muscle cells, immune and inﬂammatory cells, endothelial
cells, pericytes, and adipocytes are present in the tumor microenviron-
ment, further contributing to its complexity. Two of these cell types
are of particular interest, namely cancer-associated ﬁbroblasts (CAFs,
also referred to as tumor-associated ﬁbroblasts in the literature) and
regulatory immune cells.
3.2.1. Cancer-associated ﬁbroblasts (CAFs)
In addition to ECM components of a patient's tumor, the PDX tumor
architecture also contains, especially initially, stromal cells of the origi-
nal tumor, in particular CAFs. They form an important component of
the tumor microenvironment [1,104]. Studies with tumor xenografts,
based on co-implantation into mice of either normal ﬁbroblasts or
CAFs together with cancer cells, have been performed independently
by many groups. They consistently demonstrate signiﬁcantly increased
tumor growth-promoting potential of CAFs compared to normal ﬁbro-
blasts [105–111]. CAFs are able to produce tumor-supportive ECM and
secrete growth factors and chemokines that further alter the ECM and
generate oncogenic signals [112]. They therefore play key roles in
tumor transformation, cell proliferation and tissue invasion [113,114].
Recently, CAFs have also been found to play an important role in the de-
velopment of resistance to chemotherapy based on reduced
intratumoral drug delivery [115–118]. However, it is worth noting
that a recent clinical trial of pancreatic cancer using IPI-926, a Hedgehog
signaling inhibitor shown to deplete tumor-associated stroma [116],
has failed, suggesting that a better understanding of the intricate
tumor–stromal interactions is imperative.
Substantial evidence in vivo has shown that CAFs are critical drivers
of tumor progression in a number of organs. In the prostate, CAFs are
able to stimulate transformation of immortalized prostate epithelial
cells whereas normal ﬁbroblasts cannot [105]. Studies based on xeno-
graft models of human cells have shown that recombination of CAFs
with non-tumorigenic epithelial cells results in their permanent malig-
nant transformation [105,119]. Soluble factors secreted by CAFs such as
TGFβ, IGF1, HGF/scatter factor and other chemokines act in paracrine
fashion on adjacent epithelial cells and work in coordination with
other signaling molecules, such as ECM and integrins, to facilitate carci-
nogenesis and cancer progression [120–123]. In addition, WNT16B se-
creted by CAFs promotes an epithelial-to-mesenchymal transition
(EMT) and survival of cancer cells after cytotoxic therapy [118]. In the
case of breast cancer, there is evidence showing that molecular alter-
ations of tumor stromal cells alone can signiﬁcantly alter the behavior
and progression of tumors [124,125]. Also, CXCL12 and CXCL14, secret-
ed by CAFs in breast tumors, can increase the proliferation, tissue inva-
sion and metastasis of breast cancer cells [106,126]. These data suggest
that CAFs form a crucial component of the tumor microenvironment
and play an important role in tumorigenesis and cancer progression.
3.2.1.1. Co-culturing with CAFs. The presence of non-cancerous cell types
in the tumor microenvironment can, in part, be mimicked through co-
culturing cancer cells with cell types of interest. As the most abundant
cell type in the tumor stroma, and given their tumor-promoting abili-
ties, CAFs are frequently used in co-culture systems. Furthermore, ﬁbro-
blast and cancer cell co-culture systems have been used in combination
with 3D culture techniques and have provided more reliable in vitro
models to mimic stromal–epithelial interactions in the tumor. The abil-
ity of CAFs to promote tumorigenesis and support cancer development
and tissue invasion has been observed in such models [127–129].
One challenge in the engineering of CAF co-cultures is the heteroge-
neity of CAFs found in cancer tissues. CAFs can originate from resident
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can also be sorted, based on their histopathological features, into
myoﬁbroblasts, which are activated ﬁbroblasts expressing α-smooth
muscle actin (α-SMA), and non-myoﬁbroblasts. Thus CAFs show a
high degree of heterogeneity due to their various origins. Studies
using cancer xenograft models and genetically engineered mouse
models further suggest that different subpopulations of CAFs may play
distinct roles in tumor progression [110,130–132]. In view of this,
CAFs derived from human tumor tissues via primary cultures, contain-
ing various CAF subpopulations, likely form a clinically more relevant
supply for co-culture systems than commonly used established ﬁbro-
blast cell lines. However, signiﬁcant differences in ﬁbroblast-derived
paracrine effects on cancer cells have been observed using CAFs from
different patients, indicating an inter-tumoral heterogeneity of CAFs
[133]. Therefore, data obtained from a single CAF/cancer co-culture
system may need to be interpreted with caution. Multiple co-culture
systems based on different CAF sources may provide data that are
clinically more relevant.
3.2.2. Regulatory immune cells
Despite the advantage of PDX models in maintaining the original
tumor histology, the most commonly noted drawback is the require-
ment for an immunodeﬁcient host. While the broadly immunosuppres-
sive environment through lack of functional immune cells is essential
for tumor implantation and growth, it is also not reﬂective of the intri-
cacies of different cell types and cytokines found in the patient's
tumor microenvironment. As such, this puts major limitations on the
use of xenograft models in assessing efﬁcacy of immunotherapies
and immunomodulatory properties of certain chemotherapeutics
[134,135]. This serves to highlight, somewhat paradoxically, the immune
system as an important component of the tumor microenvironment.
Not only is there increasing clinical evidence that inﬁltration of im-
mune cells into the tumor is prognostically signiﬁcant [136–138], butTable 2
Summary of major immune cell types found in the tumor microenvironment and their role in
Immune cell subtypes Summary of functions
Anti-cancer cell types
CD8+ cytotoxic T cells Considered the predominant cell type involved in anti-can
interactions and are activated in the presence of costimula
granzymes and death ligand signaling.
Natural killer (NK) cells Eliminates cancer cells using mechanisms similar to cytoto
such as NKG2D, expressed on the cell surface.
TH1 helper T cells Upon recognition of tumor antigens, TH1 helper T cells can
that aid in the activation and expansion of cytotoxic cell ty
iNKT cells Expresses a mix of cytotoxic T cell and NK cell receptor mo
both directly and indirectly (via activation of dendritic cell
Classic (M1) macrophages Activated by IFNγ and releases high levels of pro-inﬂamma
nitrogen species. Are generally considered tumoricidal thro
of the TH1 response.
TH17 cells Characterized by the production of IL-17 family of cytokine
investigation. They seem to play a role in anti-tumor immu
TH1 cells and NK cells. However, they have also been repor
vascularization and differentiating into regulatory T cells.
Suppressive cell types
Regulatory T cells (Tregs) Considered the primary suppressive cell type in the tumor
release of anti-inﬂammatory cytokines IL-10 and TGFβ, sup
signaling, and active killing of effector cells by granzyme B
Type 2 (M2) macrophages Suppresses effector immune cell activity through IL-10, TG
development through inducing new blood and lymph vess
metalloproteinase expression, and promoting metastasis.
Plasmacytoid dendritic cells
(pDCs)
Decreases proliferation of effector T cells and increases gen
immunosuppressive cytokines and cell surface molecules s
Myeloid derived suppressor
cells (MDSCs)
Depletes arginine and sequesters cysteine to deprive effect
produces reactive nitrogen and oxygen species to disrupt a
L-selectin expression on CD8+ and CD4+ T cells to prevent
TH2 helper cells Characterized by production of IL-4, IL-5, IL-6, IL-10, and IL-
diminishing cytotoxic capacities in T cells and skewing mathe avoidance of immune destruction is considered an emerging hall-
mark of cancer [139]. Current opinions suggest that there are at least
twoways inwhich the immune system is involved in cancer. As cancers
progress and accumulate genetic alterations, the abnormalities are often
reﬂected in ways that are detectable by the immune system. Elevated
expression of tumor antigens [140] and secretion of danger signals
following chemotherapy and radiation [141,142] mark cancer cells for
elimination. The cytotoxic arm of the immune system, comprising
mainly of cytotoxic CD8+ T cells and NK cells, is thought to be responsi-
ble for cancer elimination and is aided by secretion of pro-inﬂammatory
cytokines (such as IL-2, IFNγ, TNFα) from various additional helper cell
types (Table 2). Alternatively, the regulatory, immunosuppressive arm
of the immune system is thought to inhibit normal effector cell function
in the tumormicroenvironment, causing a localized immune deﬁciency
where cancer cells can no longer be effectively eliminated and thus are
allowed to progress [143,144].
The immunosuppressive arm of the immune system is of particular
interest, as it is thought to be the predominant arm active in the
tumor microenvironment. The importance of this is exempliﬁed in
considering the challenges of eliciting anti-cancer immunity through
immunotherapeutic approaches. One major hurdle involves overcom-
ing the initial immunosuppressive tumor microenvironment [145,146]
and could be achieved through lymphodepletion prior to adoptive cell
transfer or vaccination. The depletion of host lymphocytes (either
through chemotherapy or whole body radiation) followed by hemato-
poietic stem cell transfer has been shown to increase the effectiveness
of eliciting anti-cancer immune responses [147–150]. In particular,
this approach has been shown to alter the hematopoietic stromal com-
ponents through decreasing the abundance of suppressive cell types
and abolishing the cytokine sink previously established in the tumor
microenvironment [151,152]. Furthermore, repopulation of immune
cells following transplantation is then skewed towards expansion of
anti-cancer immune cells [153] and improves effector immune cellanti-cancer immunity or immune suppression.
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tory arm of the immune system may be worth of further consideration
in creating a more relevant in vitro microenvironment.
Of the many currently known suppressive cell types (Table 2),
regulatory T cells are the best characterized and affect a wide range of
immune cells [155,156]. The association of regulatory T cellswith cancer
and the tumor microenvironment is also well established. An increased
number of regulatory T cells in the peripheral blood of patients and a
high regulatory T cell density in tumor tissue are generally correlated
with poor patient outcomes in many cancer types [157–159]. Their im-
mune suppressive properties are conferred by the transcription factor
FOXP3, and they promote tumor development by inhibiting the
cytotoxic anti-cancer response, most notably through the release of
anti-inﬂammatory cytokines IL-10 and TGFβ [160,161].
The M2 macrophages form a second subtype of regulatory immune
cells closely associated with tumor development. In addition to
suppressing the anti-cancer immune response, M2 macrophages are
known to actively promote tumor development through mechanisms
involved in tissue repair. They have been associated with the ability of
cancers to induce new blood vessel formation, remodel stromal tissue,
and dissociate connective tissue for metastasis [162,163]. The impor-
tance of M2 macrophages in cancer progression has been highlighted
in a number of studies [164–167]. Furthermore, the presence of M2
macrophages is also correlated with other signs of tumor progression,
such as elevated regulatory T cell counts, induction of angiogenesis,
and increase in lymph node metastasis [168–170]. A number of experi-
mental approaches targeting M2 macrophage involvement in cancer
have shown initial efﬁcacy in vivo and further validate the importance
of their presence in the tumor microenvironment [171–174].
Other immunosuppressive immune cell populations closely associ-
ated with developing tumors are the plasmacytoid dendritic cells
(pDCs) and the less-characterized myeloid-derived suppressor cells
(MDSCs). The immunosuppressive function of pDCs is thought to be
mediated by their ability to reduce effector T cell populations and
induce regulatory T cell development and expansion [175–177]. A num-
ber of studies have conﬁrmed the presence and function of pDCs in
various cancers [178–181]. MDSCs can further contribute to immune
suppression at the tumor site by exhibiting T cell-suppressing proper-
ties [182]. This is accomplished by both recruiting regulatory T cells
and impairing effector T cell functions through depleting arginine and
sequestering cysteine, both of which are essential nutrients required
for proper T cell proliferation [183,184]. In concordance with the previ-
ously mentioned cell types, association of MDSCs with poor prognosis
and various aspects of cancer progression is also well supported by a
number of studies [185–189].
Collectively, the evidence strongly indicates an important functional
role for immune cells in the tumor microenvironment. In particular, the
immunosuppressive regulatory subtypes seem to play an important
role in facilitating tumor progression. While most xenograft models
mimic an immunosuppressive tumor microenvironment through the
use of immunocompromised hosts, the complexity of the interactions
and balance between anti-cancer and immunosuppressive cell types
in the tumor microenvironment are often incompletely reﬂected. A
useful alternative to this would be the use of syngeneic tumor models
or other transgenic models of spontaneous cancers. Furthermore, as
certain therapeutic compounds may have immunomodulatory
properties [190–195], the use of an immune-intact system could help
elucidate whether such secondary effects would enhance or diminish
treatment efﬁcacy through stimulating or further suppressing the
anti-cancer immune response.
3.2.2.1. Co-cultures with immune cells.Given the critical importance of an
immunosuppressive tumor microenvironment in cancer development
and progression, another cell type worth considering for in vitro co-
culture systems would be immune cells. Because immune cell activities
are often responses to external stimulation by other cell types, co-cultures of cancer cells and immune cells are frequently used to assay
speciﬁc immune cell activities, including changes in cytokine produc-
tion and release [196–198], anti-cancer cytotoxic activities [199–201],
and immune cell maturation and differentiation [202,203]. Interesting-
ly, the communication between cancer cells and immune cells appears
to be bidirectional, with immune cells also modulating cancer cell
characteristics such as migratory potentials [204,205] and chemokine
production [206].
One challenge to co-culturing cancer cells and immune cells on a
regular basis in vitro is the vast diversity of the immune subtypes poten-
tially present in the tumor microenvironment. This problem is further
compounded by the fact that most tumor-associated immune cells do
not function in isolation, but rather act through intricate communica-
tion with other immune subtypes. As such, determining the exact cell
types in the correct proportions needed to mimic the tumor microenvi-
ronment is challenging. However, immune functions are oftenmodulat-
ed through secreted cytokines, and it is well documented that certain
immunosuppressive cytokines are predominantly present in the
tumor microenvironment [207–209]. More importantly, it has been
demonstrated that immunosuppressive cytokines such as TGFβ and
IL-10 can play a signiﬁcant role in promoting cancer progression
through mechanisms acting directly on cancer cells and the surround-
ing stromal cells. For example, while TGFβ has been shown to have cy-
tostatic and anti-proliferative effects in maintaining mature epithelial
tissue homeostasis [210,211], its deregulated signaling has been
shown to aid cancer development, particularly through promoting
epithelial-to-mesenchymal transition [212–214], angiogenesis [215],
metastasis [216], and stromal remodeling [217]. The presence of IL-10
has been shown to confer resistance to apoptosis [218,219]. As such,
the addition of classic immunosuppressive cytokines to the cell culture
media could be one strategy tomimic the effects of an immunosuppres-
sive tumor microenvironment on cancer cells. Interestingly, additional
cytokines commonly present in the tumor microenvironment, such as
IL-6 and IL-17, could also directly act on cancer cells and otherwise im-
pact cancer development. IL-6 has been shown to induce STAT3- and
NFκB-mediated signaling cascades in cancer cells [220], increasing cell
proliferation and protecting against apoptosis [221]. Furthermore, it
has the potential to induce chronic, cancer-promoting inﬂammation
[222,223]. Although the functional roles of IL-17 in the tumor microen-
vironment remain to be further elucidated, it has been reported to pro-
mote angiogenesis [224], cancer cell growth and survival [225]. While
there are recent advances in in vitro culture models of cancer–immune
interactions, particularly through inclusion of immune cells in various
3D model systems [226], the supplementation of such cytokines to the
culture medium in vitro, both for traditional and emerging co-culture
studies, could potentially yield more clinically relevant results.
3.3. Acidic tumor microenvironment
One ﬁnal and highly critical characteristic of the tumor microenvi-
ronment is its relatively high acidity. While an acidic tumor microenvi-
ronment is commonly observed in patients aswell as in PDXmodels, its
importance appears to be rather underappreciated in vitro. The tumor
microenvironment has elevated extracellular acidity (pH ~6.5 com-
pared to a physiological pH of 7.4) as a result of altered energy metabo-
lism. Cancer cells have long been known to exhibit an altered glucose
metabolism compared to normal cells. This phenomenonwas observed
as early as the 1920s, when OttoWarburg noted that cancer cells derive
the majority of their energy through fermentation and production of
lactic acid rather than through respiration, even under conditions of
abundant oxygen (aerobic glycolysis) [227]. The associated higher con-
sumption of glucose and also glutamine, utilization of glycolysis as the
predominant method of catabolism, excessive lactic acid generation,
and other alterations to normal metabolic pathways are collectively
considered another hallmark of cancer, common to a vast majority of
malignancies [139]. While lactic acid has previously been considered
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lism [228], there is growing evidence that increased lactic acid secretion
plays an active role in shaping the tumor microenvironment to support
cancer survival.
A common perspective on the purpose of excessive lactic acid
production by cancers is that altered energy metabolism confers a
proliferative advantage to them [228–230]. While it is puzzling that
cancer cells opt for aerobic glycolysis that generates ATP at an 18-fold
lower efﬁciency than oxidative phosphorylation, the predominant
theory suggests that the advantage lies in the incomplete utilization of
glucose. This allows upstream intermediates to be redirected for biosyn-
thesis and gives cancer cells abundant building blocks for the synthesis
of cellular components [230]. Another explanation that has been offered
is that aerobic glycolysis arose as an adaptation to hypoxic conditions
commonly experienced in tumors, which often encounter ﬂuctuating
oxygen levels, periodically alternating between normoxic and hypoxic
conditions [231,232]. A dependence on glycolysis regardless of oxygen
levels could therefore confer a proliferative advantage to cancer cells,
making them less susceptible to hypoxic stress during episodes of spon-
taneous hypoxia, even if such protection comes at the cost of reduced
energy production during times of adequate oxygenation [228]. Howev-
er, as theﬁeld is rapidly advancing, recent studies have indicated that al-
terations to cancer cellmetabolismmay actually be a result of oncogenic
transformation. Genetic alterations to various classic cancer-associated
pathways (such as Myc, PI3K, AMPK, and p53) have been shown to
alter metabolic patterns in favor of glycolysis [233–236]. Furthermore,
in addition to altering glucose metabolism, increased glutamine utiliza-
tion in excess of nitrogen requirements has also been observed. This has
been shown in particular to facilitate fatty acid biosynthesis through use
of TCA cycle intermediates and also results in excessive lactate produc-
tion [237,238]. Such alterations to glutamine metabolism could also
modulate apoptosis, particularly in light of its importance in glutathione
synthesis and maintenance of cellular redox states [239,240].
In addition to proliferation and survival, many other advantages
affecting multiple aspects fundamental to cancer biology have been as-
cribed to increased production of lactic acid and subsequent acidiﬁca-
tion of the tumor microenvironment. One such aspect is the ability of
cancer cells to invade local tissue and ultimately metastasize. It has
been found that cancer-adjacent normal tissue is also subjected to in-
creased acidity, making it more susceptible to cancer invasion [241].
The regions of highest tumor invasion corresponded to areas of lowest
pH; tumor invasion did not occur in regions with normal or near-
normal extracellular pH. Also, cancer cells in the invasive edge of tumors
were found to upregulate proteins in acid-generating pathways such as
the glucose transporter GLUT-1 and the sodium–hydrogen exchanger
NHE-1 [242]. Furthermore, lactate transporters are conﬁned to the
leading edge of lamellipodia and play a role in human cancer cell
invasiveness [243,244]. Additionally, studies have shown that an acidic
extracellular environment can induce expression and secretion of
various proteases commonly found in the tumor microenvironment
associated with ECM degradation [245–247]. As such, an acidic tumor
microenvironment is an important contributing factor to tissue invasion
and metastasis of cancer cells via a combination of toxicity to adjacent
normal cells, degradation of the ECM through secreted and activated
proteases, and increased cancer cell motility.
The excessive lactic acid generation by cancer cells also has a
profound effect on angiogenesis. It has recently been shown that extra-
cellular lactate can stimulate endothelial cell growth through signaling
mechanisms involving receptor tyrosine kinases [248]. This lends
further evidence to claims that lactic acid is a driving force behind
angiogenesis [249]. It has been shown that endothelial cells use lactate
transporters to import lactic acid from the environment, causing an ac-
tivation of HIF-1α and stimulation of the NFκB/IL-8 pathway for tumor
angiogenesis [250,251]. Furthermore, lactic acid is also able to induce
VEGF production in macrophages and endothelial cells to stimulate
endothelial cell migration [252].The effectiveness of certain chemotherapeutic agents is known to be
altered in the acidic tumor microenvironment. In particular, the acidic
gradient can negatively affect the efﬁcacy of common weak base
chemotherapies [253,254]. The semi-permeable nature of the cellmem-
brane allows small, uncharged molecules to readily diffuse into the cell
and excludes charged ionic species. For weakly basic therapeutics such
as mitoxantrone, doxorubicin, and topotecan, the acidic extracellular
environment in the tumor results in an accumulation of the charged
species in the extracellular space and greatly decreases their efﬁcacy
[255,256]. Furthermore, the acidic microenvironment can also enhance
the activity of known drug transporters such as p-glycoproteins and
confer an additional mechanism of drug resistance through increased
efﬂux [257,258]. However, the acidic tumor environment can also be
exploited for therapeutic purposes. The uncharged form of weak acids
is favored in an acidic environment and permeability through the cell
membrane is improved. As such, an increased efﬁcacy is observed for
compounds such as chlorambucil and melphalan [259,260], and nano-
particle drug delivery systems engineered to release their contents in
an acidic environment also have the potential for enhanced speciﬁcity
for tumor tissue [261].
Finally, one largely ignored effect of the acidic tumor microenviron-
ment is local suppression of the anti-cancer immune response. The
immune system has long been known to be highly dependent on the
surrounding environment for function, whether through the presence
of cytokines or various helper cells. There is increasing evidence in the
literature to suggest that alterations to the extracellular pH, particularly
an increase in acidity, can greatly hamper normal immune cell functions
[198,262–264]. It has been shown that under acidic conditions, tumor-
inﬁltrating T lymphocytes became anergic andwere unable to eliminate
cancer cells both in vitro and in vivo. This inhibition, however, was
found to be reversible as cytotoxic capacities were restored when the
extracellular pHwas reverted to physiological levels [198,265]. Further-
more, the presence of lactic acid also altered the differentiation and
antigen presentation abilities of dendritic cells [266] and skewed the
differentiation pattern of tumor-associated macrophages towards the
suppressive M2 phenotype [264]. Considering the important role that
the immune system plays in cancer development and progression as
mentioned above, we recently summarized the evidence suggesting
that the extracellular pH plays an equally important role in modulating
immune function and proposed that cancer-generated lactic acid could
be viewed as an immunosuppressive regulatory metabolite rather than
a simple waste product [267].
Taken together, it is clear that an acidic tumor microenvironment
has profound inﬂuences on multiple cancer characteristics including
cell proliferation, tissue invasion/metastasis, angiogenesis, treatment
resistance, and evasion of immune destruction. As such, it is crucial to
take the effects of an acidic extracellular environment into account
regardless of the aspect of cancer biology studied or the model system
used.
3.3.1. Acidic culture conditions
While in vivo systems can approximate the acidic tumor microenvi-
ronment commonly seen in patients, most in vitro cell culture systems
completely ignore this aspect of cancer biology. Cancer cells are routine-
ly grown in a culture medium buffered to a physiological pH of 7.4.
While such optimal pH conditions may be most beneﬁcial to the health
and proliferation of the cells, they do not reﬂect the environment of
cancer cells in patients' tumors, which can be as acidic as pH b6.5. As
mentioned above, the acidic tumor microenvironment induced by ex-
cessive lactic acid generation plays a critical role in multiple fundamen-
tal aspects of cancer biology. The use of a non-acidic condition in vitro
could in part account for the discrepancies often observed between
results obtained in vitro and in vivo.
The issue of the acidic tumormicroenvironment becomes evenmore
critical when we consider evidence from the literature documenting
enormous changes to cancer cells when they are cultured under acidic
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ry potential [245,268] and altering drug sensitivity [269,270], an acidic
culture condition can have profound effects on other aspects of cancer.
Changes to metabolic patterns have been observed when cancer cells
are cultured in acidic conditions, with a switch from reliance on aerobic
glycolysis and production of lactic acid under a physiological pH to a re-
version back to oxidative phosphorylation in an acidic environment
[271]. Furthermore, culturing cancer cells in an acidic environment
have also been demonstrated to increase autophagic ﬂux [272] and re-
duce cell sensitivity to radiation therapy, potentially throughprolonging
the G2/M cell cycle arrest and allowing more time for repairing
radiation-induced damage [273,274]. The lowering of the extracellular
pH also results in a decreased intracellular pH in cancer cells, resulting
in global histone deacetylation and corresponding global alterations to
gene expression patterns [275]. The vast changes observed by simply al-
tering the extracellular pH are not limited to cancer cells. As previously
mentioned, an increased extracellular acidity as a result of altered can-
cer metabolism can have profound effects on the angiogenic potentials
of endothelial cells [250,251] as well as the anti-cancer function of
tumor-inﬁltrating immune cells [198,267].
Use of co-cultures of cancer cells and cancer-associated cell types of
interest in an optimalmolecular environment, adjusted to beminimally
disruptive to cell growth and proliferation, allows the introduction of
many artiﬁcial changes. In view of the important role that an acidic
tumor microenvironment plays in regulating multiple crucial aspects
of cancer biology, lowering the pH of the culture medium to valuesFig. 2. Aspects of tumor biology affected by an acidic extracellular environment asmimicked by
associated stromal cells, including altered energy metabolism, increased tissue invasion, increa
an acidic culture condition more closely reﬂects the tumor microenvironment and should be cobserved in in vivo tumors could be a simple yet critical adjustment to
making in vitro studies more reﬂective of real tumor conditions.
4. Conclusions and caveats
While in vitro cell culture models allow a more detailed and conve-
nient analysis of cancer-related properties and processes, it is becoming
increasingly evident that the use of simpliﬁed cell growth conditions
may unwittingly lead to experimental observations that do not accu-
rately reﬂect tumor physiology. There is abundant evidence in the liter-
ature suggesting that alterations to in vitro culture conditions can have
drastic consequences for cancer cell biology and may lead to misinter-
pretations of the results. Given that PDX models often demonstrate
the highly heterogeneous nature of patients' tumors, the use of the xe-
nograft sublines that best meet the desired molecular and phenotypic
characteristics for experimentation is of critical importance.
However, similar to any other cancer modeling system, PDXs have
their inherent limitations and deﬁciencies. As mentioned previously,
the lack of a fully functional human immune system presents a major
challenge. To circumvent this limitation, more sophisticated PDX
models (humanized models) should be developed via co-grafting of
tumor tissue along with bone marrow stem cells of the same patient
similar to approaches in developing humanized immune systems in
mice [276,277]. This combinationmay reconstitute the human immune
system and allow investigation into the role of the immune system in
cancer metastasis as well as the efﬁcacy of immune-based therapies.an acidic culture condition. Profound changes are observed in both cancer cells and tumor-
sed angiogenesis, altered therapeutic efﬁcacies, and impaired immune cell functions. Such
onsidered when engineering in vitro conditions that are more physiologically relevant.
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pathological andmolecular differences between patient tumors and xe-
nografts are foreseeable following continual passaging. It is therefore
prudent to establish cryopreservation of PDXs at an early generation,
ensuring the preservation of the cellular and molecular characteristics
of the original tumor and an unlimited supply of a particular patient's
tumor. Last but not least, the high cost and amount of human resources
associated with their use, compared to traditional cell line-based sys-
tems, form another major factor hampering the widespread use of
PDX models. However, these downsides are counteracted by the in-
creased clinical relevance of the PDX cancer models, compared to
other existing models, as it is a most critical requirement for cancer
models in drug development.
We know that while many aspects of using in vivo animal cancer
models are beneﬁcial, there are also many inaccuracies associated
with current approaches. Investigators have been very successful at
“curing” mice from numerous cancers, but unfortunately these “cures”
cannot always be repeated in humans during clinical trials. Clearly, a
better pre-clinical balance between improved in vitro mimicry and
selecting animal models that are more closely related to the clinical
scenario is needed. As discussed above, the crucial aspects of the
tumor microenvironment include tumor architecture, various cell–cell
interactions, and an acidic microenvironment. By mimicking these fun-
damental components through 3D cultures, co-culture systems, and
acidic culture conditions, in vitro models of tumor physiology may be
improved to render results with increased clinical relevance.
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